Semiannual Report — FY2026 H1
What PhoenixBio Co.,Ltd. reported for the period from 2026-04-01 to 2027-03-31. Filed by 株式会社フェニックスバイオ
Filed 2026-11-13View the original on EDINET
How much it says
33Thin
What moved here
3named for the first time
Its own wording
14terms
Which filing this is
37/ 37newest
No officer data yetThis company's filings have not been read for officers yet. Nothing is missing from the filings — the roster simply has not been extracted.
The gist
During the interim consolidated accounting period, contract testing services and sales of related products performed well in Japan, supported by factors including expanded adoption of PXB mice. Overseas, however, contract testing projects were lost because major customers constrained their R&D budgets, causing revenue to fall below the same period of the previous year and resulting in an operating loss. There were no material changes in material business and other risks during the interim consolidated accounting period, and capital investment was recorded as expenditure for the acquisition of property, plant and equipment.
Komori's summary of this document, not the document's own words.33Thin
How much this filing saysA weighted roll-up of 9 rubric dimensions, each scored from a fixed set of questions asked against this filing — built only from the 32 this document could answer. It measures how specific the disclosure is, not whether the company is doing well. Derived from the data, not editorial.
52
Typical
38
Thin
42
Thin
50
Typical
12
Almost nothing
0
Almost nothing
7
Almost nothing
35
Thin
50
Typical
R&D spend88百万円Money spent making new things.
Cash left over-1億円Cash from the business, less what went into equipment.
Spent on equipment4百万円Plants, machines — things meant to last.
EmployeesNot disclosedThis document does not carry the figure.
How to read this page
This is not the documentIt is Komori's reading of the filing submitted to EDINET. The original is linked above.
The score is not a verdictIt measures how specific the disclosure is. It says nothing about results or where the share price goes.
When it updatesContent lands once the filing has been read through. Right after submission, the summary can still be empty.